Patents by Inventor Konstantinos Chatzistergos

Konstantinos Chatzistergos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210145893
    Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
    Type: Application
    Filed: June 26, 2020
    Publication date: May 20, 2021
    Inventors: Joshua HARE, Konstantinos CHATZISTERGOS, Alan W. HELDMAN
  • Patent number: 10874698
    Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 29, 2020
    Assignee: VESTION, INC.
    Inventors: Joshua Hare, Konstantinos Chatzistergos, Alan W. Heldman
  • Publication number: 20200246389
    Abstract: The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 6, 2020
    Inventors: Joshua M. Hare, Konstantinos Chatzistergos
  • Patent number: 10709742
    Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: July 14, 2020
    Assignee: VESTION, INC.
    Inventors: Joshua Hare, Konstantinos Chatzistergos, Alan W. Heldman
  • Publication number: 20200166498
    Abstract: Methods of isolating cardiac cells, including cardiac cells capable of regenerating cardiac tissue are provided. Compositions comprising cardiac cells, including cardiac cells capable of regenerating cardiac tissue are also provided. Methods of using cardiac cells, cardiac progenitor cells, including cardiac cells capable of regenerating cardiac tissue, are provided. Methods of identifying the prognosis of patients treated for heart disease and/or methods of predicting the regeneration of cardiac cells in a subject are also provided.
    Type: Application
    Filed: November 11, 2019
    Publication date: May 28, 2020
    Inventors: Joshua HARE, Konstantinos CHATZISTERGOS
  • Patent number: 10481147
    Abstract: Methods of isolating cardiac cells, including cardiac cells capable of regenerating cardiac tissue are provided. Compositions comprising cardiac cells, including cardiac cells capable of regenerating cardiac tissue are also provided. Methods of using cardiac cells, cardiac progenitor cells, including cardiac cells capable of regenerating cardiac tissue, are provided. Methods of identifying the prognosis of patients treated for heart disease and/or methods of predicting the regeneration of cardiac cells in a subject are also provided.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: November 19, 2019
    Assignee: VESTION, INC.
    Inventors: Joshua Hare, Konstantinos Chatzistergos
  • Publication number: 20190076481
    Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
    Type: Application
    Filed: May 7, 2018
    Publication date: March 14, 2019
    Inventors: Joshua HARE, Konstantinos CHATZISTERGOS, Alan W. HELDMAN
  • Publication number: 20190076480
    Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
    Type: Application
    Filed: May 7, 2018
    Publication date: March 14, 2019
    Inventors: Joshua Hare, Konstantinos Chatzistergos, Alan W. Heldman
  • Publication number: 20180180592
    Abstract: Methods of isolating cardiac cells, including cardiac cells capable of regenerating cardiac tissue are provided. Compositions comprising cardiac cells, including cardiac cells capable of regenerating cardiac tissue are also provided. Methods of using cardiac cells, cardiac progenitor cells, including cardiac cells capable of regenerating cardiac tissue, are provided. Methods of identifying the prognosis of patients treated for heart disease and/or methods of predicting the regeneration of cardiac cells in a subject are also provided.
    Type: Application
    Filed: July 24, 2017
    Publication date: June 28, 2018
    Inventors: Joshua HARE, Konstantinos CHATZISTERGOS
  • Patent number: 9980985
    Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: May 29, 2018
    Assignee: Vestion, Inc.
    Inventors: Joshua Hare, Konstantinos Chatzistergos, Alan W. Heldman
  • Patent number: 9962409
    Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: May 8, 2018
    Assignee: Vestion, Inc.
    Inventors: Joshua Hare, Konstantinos Chatzistergos
  • Patent number: 9746457
    Abstract: Methods of isolating cardiac cells, including cardiac cells capable of regenerating cardiac tissue are provided. Compositions comprising cardiac cells, including cardiac cells capable of regenerating cardiac tissue are also provided. Methods of using cardiac cells, cardiac progenitor cells, including cardiac cells capable of regenerating cardiac tissue, are provided. Methods of identifying the prognosis of patients treated for heart disease and/or methods of predicting the regeneration of cardiac cells in a subject are also provided.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: August 29, 2017
    Assignee: Vestion, Inc.
    Inventors: Joshua Hare, Konstantinos Chatzistergos
  • Publication number: 20150316535
    Abstract: Methods of isolating cardiac cells, including cardiac cells capable of regenerating cardiac tissue are provided. Compositions comprising cardiac cells, including cardiac cells capable of regenerating cardiac tissue are also provided. Methods of using cardiac cells, cardiac progenitor cells, including cardiac cells capable of regenerating cardiac tissue, are provided. Methods of identifying the prognosis of patients treated for heart disease and/or methods of predicting the regeneration of cardiac cells in a subject are also provided.
    Type: Application
    Filed: December 2, 2013
    Publication date: November 5, 2015
    Inventors: Joshua HARE, Konstantinos CHATZISTERGOS
  • Publication number: 20140369976
    Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventors: Joshua HARE, Konstantinos CHATZISTERGOS, Alan W. HELDMAN
  • Publication number: 20100260727
    Abstract: Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
    Type: Application
    Filed: March 31, 2010
    Publication date: October 14, 2010
    Applicant: UNIVERSITY OF MIAMI
    Inventors: Joshua Hare, Konstantinos Chatzistergos